psoriasis

Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Indirect[...]

Guo L, Bilimoria SN, Kikuchi R, Hao A, Sadrolashrafi K, Yamamoto RK, Tolson H, Yee D, Armstrong AW. Chronic Obstructive Pulmonary Disease Outcomes in Psoriasis[...]

Warren RB, Donnelly K, Kiri S, Taieb V, Slim M, Fahrbach K, Neupane B, Betts M, Armstrong A. Long-Term Efficacy and Safety of Bimekizumab and[...]

Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee[...]

Armstrong AW, Foley P, Liu Y, Miller M, Teneralli RE, Bewley A, Gordon KB, Papp KA, Han C. Direct and Indirect Effect of Guselkumab on[...]

James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB, Lee LW, Merola J, Schwartzman S, Gladman D, Liu C, Koo J, Hawkes[...]

Guo L, Bilimoria SN, Kikuchi R, Hao A, Tolson H, Yamamoto RK, Sadrolashrafi K, Yee D, Armstrong AW. Prevalence, Incidence, and Risk of Chronic Obstructive[...]

Korman NJ, Warren RB, Bagel J, Armstrong AW, Gooderham M, Strober B, Thaçi D, Morita A, Imafuku S, Foley P, Sofen H, Zheng M, Hippeli[...]

Armstrong AW, Park SH, Patel V, Nicolas P, Wang WJ, Colombo MJ, Chirikov V. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to[...]

Gebauer K, Spelman L, Yamauchi PS, Bagel J, Nishandar T, Crane M, Kopeloff I, Kothekar M, Yao SL, Sofen HL. Efficacy and safety of tildrakizumab[...]